MX2019012570A - Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario. - Google Patents
Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.Info
- Publication number
- MX2019012570A MX2019012570A MX2019012570A MX2019012570A MX2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A MX 2019012570 A MX2019012570 A MX 2019012570A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- receptor molecule
- veterinary use
- contiguous
- polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5406—IL-4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5437—IL-13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488509P | 2017-04-21 | 2017-04-21 | |
| PCT/US2018/028507 WO2018195388A1 (en) | 2017-04-21 | 2018-04-20 | Il4/il13 receptor molecule for veterinary use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019012570A true MX2019012570A (es) | 2019-12-02 |
Family
ID=63856393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012570A MX2019012570A (es) | 2017-04-21 | 2018-04-20 | Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11970526B2 (https=) |
| EP (1) | EP3612555A4 (https=) |
| JP (2) | JP7657548B2 (https=) |
| KR (2) | KR20200006528A (https=) |
| CN (1) | CN110770250B (https=) |
| AU (2) | AU2018254542B2 (https=) |
| BR (1) | BR112019021812A2 (https=) |
| CA (1) | CA3059731A1 (https=) |
| MX (1) | MX2019012570A (https=) |
| NZ (1) | NZ757956A (https=) |
| WO (1) | WO2018195388A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| US11970526B2 (en) | 2017-04-21 | 2024-04-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| BR112020002871A2 (pt) * | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| BR112022021204A2 (pt) * | 2020-04-22 | 2022-12-06 | Kindred Biosciences Inc | Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra |
| EP4165066A4 (en) * | 2020-06-12 | 2024-08-14 | Beijing Vdjbio Co., Ltd. | FUSION POLYPEPTIDE |
| MX2024002149A (es) | 2021-08-20 | 2024-03-08 | Intervet Int Bv | Proteinas de fusion para tratar la dermatitis atopica. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6428788B1 (en) | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US7083949B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| PT1141286E (pt) | 1998-12-14 | 2007-01-31 | Genetics Inst Llc | Cadeia de receptores de citocina |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| WO2001077332A2 (en) | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| WO2005032399A2 (en) | 2003-05-30 | 2005-04-14 | The Regents Of The University Of California | Il4 receptor antagonists for horse, dog and cat |
| SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
| AU2005219837A1 (en) * | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
| CN1922204A (zh) | 2004-02-27 | 2007-02-28 | 瑞泽恩制药公司 | Il－4/il－13特异性的多肽和其治疗应用 |
| US8354109B2 (en) | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| EP2674440B1 (en) * | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| WO2008073463A2 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| WO2009061911A1 (en) * | 2007-11-06 | 2009-05-14 | Wyeth | Assays and methods for evaluating multimeric complexes |
| EP2220125A4 (en) | 2007-11-13 | 2010-12-29 | Sapphire Energy Inc | PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE |
| EP2702069A4 (en) | 2011-04-29 | 2015-04-29 | Janssen Biotech Inc | IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF |
| ES2710384T3 (es) * | 2011-12-13 | 2019-04-24 | Pieris Pharmaceuticals Gmbh | Procedimientos para la prevención o el tratamiento de determinados trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores |
| EP2850093B1 (en) * | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| AU2016239858B2 (en) | 2015-04-02 | 2021-07-01 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| EA201890391A1 (ru) * | 2015-07-29 | 2018-08-31 | НАНОТИКС, ЭлЭлСи | Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| US11970526B2 (en) | 2017-04-21 | 2024-04-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| US12428466B2 (en) | 2018-10-25 | 2025-09-30 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| BR112022021204A2 (pt) | 2020-04-22 | 2022-12-06 | Kindred Biosciences Inc | Polipeptídeos, proteínas heterodiméricas, ácido nucleico, células hospedeiras, método, composição farmacêutica e método de tratamento de uma espécie de animal de companhia, métodos para reduzir a atividade de sinalização de il13 e/ou il4 e para detectar il13 ou il4 em uma amostra |
-
2018
- 2018-04-20 US US16/605,356 patent/US11970526B2/en active Active
- 2018-04-20 KR KR1020197032241A patent/KR20200006528A/ko not_active Ceased
- 2018-04-20 EP EP18788175.0A patent/EP3612555A4/en active Pending
- 2018-04-20 BR BR112019021812-2A patent/BR112019021812A2/pt unknown
- 2018-04-20 WO PCT/US2018/028507 patent/WO2018195388A1/en not_active Ceased
- 2018-04-20 CA CA3059731A patent/CA3059731A1/en active Pending
- 2018-04-20 MX MX2019012570A patent/MX2019012570A/es unknown
- 2018-04-20 KR KR1020257012785A patent/KR20250057131A/ko active Pending
- 2018-04-20 JP JP2019556941A patent/JP7657548B2/ja active Active
- 2018-04-20 CN CN201880041160.7A patent/CN110770250B/zh active Active
- 2018-04-20 AU AU2018254542A patent/AU2018254542B2/en active Active
- 2018-04-20 NZ NZ757956A patent/NZ757956A/en unknown
-
2023
- 2023-02-27 JP JP2023028068A patent/JP7776461B2/ja active Active
- 2023-03-20 AU AU2023201726A patent/AU2023201726B2/en active Active
-
2024
- 2024-03-27 US US18/617,972 patent/US20240270820A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023078158A (ja) | 2023-06-06 |
| EP3612555A4 (en) | 2020-12-30 |
| US20200048325A1 (en) | 2020-02-13 |
| EP3612555A1 (en) | 2020-02-26 |
| AU2018254542A1 (en) | 2019-11-21 |
| WO2018195388A1 (en) | 2018-10-25 |
| CN110770250B (zh) | 2025-01-07 |
| US20240270820A1 (en) | 2024-08-15 |
| AU2023201726B2 (en) | 2024-11-21 |
| AU2023201726A1 (en) | 2023-04-27 |
| KR20200006528A (ko) | 2020-01-20 |
| RU2019137211A (ru) | 2021-05-21 |
| US11970526B2 (en) | 2024-04-30 |
| JP2020517262A (ja) | 2020-06-18 |
| JP7776461B2 (ja) | 2025-11-26 |
| CA3059731A1 (en) | 2018-10-25 |
| CN110770250A (zh) | 2020-02-07 |
| JP7657548B2 (ja) | 2025-04-07 |
| BR112019021812A2 (pt) | 2020-05-26 |
| RU2019137211A3 (https=) | 2021-09-09 |
| AU2018254542B2 (en) | 2022-12-22 |
| KR20250057131A (ko) | 2025-04-28 |
| NZ757956A (en) | 2026-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019012570A (es) | Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario. | |
| MX2024012304A (es) | Anticuerpos anti-il31 para uso veterinario | |
| CY1123441T1 (el) | Μορια με ειδικοτητα στα cd45 και cd79 | |
| CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
| MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
| MX2020002626A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores. | |
| CO2020001981A2 (es) | Proteínas que se unen a nkg2d, cd16 y flt3 | |
| AR120223A1 (es) | Proteínas que unen nkg2d, cd16 y flt3 | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| PE20170256A1 (es) | Proteinas de union y sus metodos de uso | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| MX2016011993A (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas. | |
| PE20161403A1 (es) | Evento de maiz transgenico mon 87419 y metodos para su uso | |
| CL2016000293A1 (es) | Diacuerpos fc monovalentes biespecíficos que son capaces de unirse a cd32b y cd79b y usos de los mismos | |
| PT3250048T (pt) | Composições de oligossacáridos para utilização como ração para animais e métodos para a sua produção | |
| AR100168A1 (es) | Proteínas agonistas de los receptores de trail de cadena simple | |
| MX2020008403A (es) | Receptores de celulas t especificos de ciclina a1 y usos de los mismos. | |
| CL2018001427A1 (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación. | |
| EP3561059C0 (en) | COMPOSITION FOR BASE EDITING FOR AN ANIMAL EMBRYO AND METHOD OF BASE EDITING | |
| EP4101310C0 (en) | Flavor enhancers for pet food, preparation method and their uses | |
| MX2024013356A (es) | Anticuerpos anti alfa-sinucleina | |
| BR112022002771A2 (pt) | Anticorpos anti-il31 para uso veterinário | |
| CO2019009035A2 (es) | Proteínas de unión al receptor de glucagón y métodos para usarlas | |
| MX395721B (es) | Composiciones y metodos para caninos pequeños. | |
| CO2019006663A2 (es) | Polipéptidos de unión y métodos para fabricarlos |